ANDA 79224, held by Gland Pharma Ltd. Ondansetron Hydrochloride.
As of Nov 16, 2026, ANDA 79224 (Ondansetron Hydrochloride), held by Gland Pharma Ltd, was first approved by FDA on Sep 25, 2009, with 8 approved supplements and 0 published complete response letters.
Ondansetron Injection is a 5-HT 3 receptor antagonist indicated for the prevention of:
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 25, 2009 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Ondansetron HydrochlorideEQ 2MG BASE/ML · injectable;injection | Ondansetron Hydrochloride | Rx |
| Nov 17, 2025 | Supplement 23Labeling · Standard review | Approved | None posted |
| Mar 11, 2022 | Supplement 18Labeling · Standard review | Approved | None posted |
| Aug 18, 2021 | Supplement 11Labeling · Standard review | Approved | None posted |
| Aug 18, 2021 | Supplement 17Labeling · Standard review | Approved | None posted |
| Jan 9, 2015 | Supplement 5Labeling · Standard review | Approved | None posted |
| Jan 9, 2015 | Supplement 6Labeling · Standard review | Approved | None posted |
| Jun 30, 2013 | Supplement 2Labeling · Standard review | Approved | None posted |
| Jun 30, 2013 | Supplement 4Labeling · Standard review | Approved | None posted |
| Sep 25, 2009 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters